2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee.

PubWeight™: 3.92‹?› | Rank: Top 1%

🔗 View Article (PMID 18079354)

Published in Circulation on December 13, 2007

Authors

Spencer B King, Sidney C Smith, John W Hirshfeld, Alice K Jacobs, Douglass A Morrison, David O Williams, 2005 WRITING COMMITTEE MEMBERS, Ted E Feldman, Morton J Kern, William W O'Neill, Hartzell V Schaff, Patrick L Whitlow, Cynthia D Adams, Jeffrey L Anderson, Christopher E Buller, Mark A Creager, Steven M Ettinger, Jonathan L Halperin, Sharon A Hunt, Harlan M Krumholz, Frederick G Kushner, Bruce W Lytle, Rick Nishimura, Richard L Page, Barbara Riegel, Lynn G Tarkington, Clyde W Yancy

Articles citing this

(truncated to the top 100)

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80

Genomics and drug response. N Engl J Med (2011) 4.35

Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Arch Intern Med (2011) 3.73

Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation (2010) 3.42

Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (2011) 2.68

Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther (2011) 1.69

Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J (2010) 1.53

A randomized controlled trial of positive-affect induction to promote physical activity after percutaneous coronary intervention. Arch Intern Med (2012) 1.52

Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38

Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol (2010) 1.27

Diagnostic-therapeutic cascade revisited: coronary angiography, coronary artery bypass graft surgery, and percutaneous coronary intervention in the modern era. Circulation (2008) 1.21

Use of noninvasive ventilation in patients with acute respiratory failure, 2000-2009: a population-based study. Ann Am Thorac Soc (2013) 1.17

Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc (2009) 1.16

Aging might increase myocardial ischemia / reperfusion-induced apoptosis in humans and rats. Age (Dordr) (2011) 1.13

Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One (2011) 1.10

Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc (2009) 1.00

Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet (2013) 0.99

Cardiac progenitor cells and bone marrow-derived very small embryonic-like stem cells for cardiac repair after myocardial infarction. Circ J (2010) 0.99

Bleeding complications after pacemaker or cardioverter-defibrillator implantation in patients receiving dual antiplatelet therapy: Results of a prospective, two-centre registry. Neth Heart J (2010) 0.94

Acute coronary syndromes: Diagnosis and management, part II. Mayo Clin Proc (2009) 0.93

Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol (2010) 0.91

Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord (2010) 0.90

Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry. Am J Cardiol (2012) 0.90

Drug-eluting stents in patients with chronic kidney disease: a prospective registry study. PLoS One (2010) 0.90

Fractional flow reserve versus angiography in left circumflex ostial intervention after left main crossover stenting. Korean Circ J (2011) 0.90

Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J (2010) 0.90

Coronary pressure-derived fractional flow reserve in the assessment of coronary artery stenoses. Eur Radiol (2012) 0.87

Review of Currently Available GP IIb/IIIa Inhibitors and Their Role in Peripheral Vascular Interventions. Semin Intervent Radiol (2010) 0.87

Rethinking cocaine-associated chest pain and acute coronary syndromes. Mayo Clin Proc (2011) 0.86

Biliary-Pancreatic Endoscopic and Surgical Procedures in Patients under Dual Antiplatelet Therapy: A Single-Center Study. Clin Endosc (2013) 0.86

Acupuncture for chronic, stable angina pectoris and an investigation of the characteristics of acupoint specificity: study protocol for a multicenter randomized controlled trial. Trials (2014) 0.86

Effects of preoperative aspirin on cardiocerebral and renal complications in non-emergent cardiac surgery patients: a sub-group and cohort study. PLoS One (2012) 0.86

The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. Korean Circ J (2010) 0.85

A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program. Trials (2010) 0.85

Prognostic value of coronary artery calcium score in patients with stable angina pectoris after percutaneous coronary intervention. J Geriatr Cardiol (2014) 0.85

Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States. Am Heart J (2013) 0.84

Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials (2013) 0.84

New antithrombotic agents--insights from clinical trials. Nat Rev Cardiol (2010) 0.84

Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol (2011) 0.84

Health-related quality-of-life after percutaneous coronary intervention in patients with UA/NSTEMI and STEMI: the Korean multicenter registry. J Korean Med Sci (2013) 0.83

Long-Term clinical outcomes according to initial management and thrombolysis in myocardial infarction risk score in patients with acute non-ST-segment elevation myocardial infarction. Yonsei Med J (2009) 0.83

Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response. Indian Heart J (2013) 0.83

Expansion of the Multi-Link Frontier™ coronary bifurcation stent: micro-computed tomographic assessment in human autopsy and porcine heart samples. PLoS One (2011) 0.82

Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent. Circ Cardiovasc Qual Outcomes (2011) 0.82

Impact of clinical urgency, physician supply and procedural capacity on regional variations in wait times for coronary angiography. BMC Health Serv Res (2010) 0.82

Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program. Vasc Health Risk Manag (2009) 0.81

Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract (2012) 0.81

Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials (2010) 0.81

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.81

Impact of stress testing before percutaneous coronary intervention or medical management on outcomes of patients with persistent total occlusion after myocardial infarction: analysis from the occluded artery trial. Am Heart J (2009) 0.80

Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. ISRN AIDS (2013) 0.80

Remote Zone Extracellular Volume and Left Ventricular Remodeling in Survivors of ST-Elevation Myocardial Infarction. Hypertension (2016) 0.80

Current strategies to minimize the bleeding risk of warfarin. J Blood Med (2013) 0.79

Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol (2012) 0.79

Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol (2011) 0.79

The importance of cardiac biomarkers on remodelling after myocardial infarction. J Clin Med Res (2012) 0.79

How do We Manage Coronary Artery Disease in Patients with CKD and ESRD? Electrolyte Blood Press (2014) 0.78

Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population. PLoS One (2012) 0.78

Assessment of clopidogrel on the left ventricular ejection fraction in acute myocardial infarction. Int J Prev Med (2010) 0.78

Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. Genet Med (2015) 0.77

Applications of optical coherence tomography in cardiovascular medicine, Part 2. J Nucl Cardiol (2009) 0.77

Dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease. ISRN Cardiol (2013) 0.77

Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies. Pharmaceuticals (Basel) (2010) 0.77

Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents. World J Cardiol (2014) 0.77

Description of a Heart Team approach to coronary revascularization and its beneficial long-term effect on clinical events after PCI. Clin Res Cardiol (2015) 0.76

The adaptive neuroplasticity hypothesis of behavioral maintenance. Neural Plast (2012) 0.76

Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction. Int J Clin Exp Med (2015) 0.76

Role of sodium tungstate as a potential antiplatelet agent. Drug Des Devel Ther (2015) 0.76

Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study. J Interv Cardiol (2013) 0.75

Bleeding complication of triple therapy of rivaroxaban, prasugrel, and aspirin: a case report and general discussion. Case Rep Cardiol (2014) 0.75

Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study. Scientifica (Cairo) (2016) 0.75

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. Vasc Health Risk Manag (2010) 0.75

What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve? Interact Cardiovasc Thorac Surg (2012) 0.75

Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. Mayo Clin Proc (2009) 0.75

Comparison of coronary artery bypass grafting with percutaneous coronary intervention for unprotected left main coronary artery disease. Yonsei Med J (2012) 0.75

Angiotensin II Type 1 Receptor Gene A1166C Polymorphism Was Not Associated With Acute Coronary Syndrome in an Iranian Population. Iran Red Crescent Med J (2016) 0.75

Impact of SYNTAX score on 1-year clinical outcomes in patients undergoing percutaneous coronary intervention for unprotected left main coronary artery. Am J Cardiovasc Dis (2012) 0.75

Short-Term Left Ventricular Remodeling After Revascularization in Subacute Total and Subtotal Occlusion With the Infarct-Related Left Anterior Descending Artery. Cardiol Res (2011) 0.75

Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol (2014) 0.75

Early surgery after coronary revascularization: a fine line between bleeding and thrombosis. Transl Med UniSa (2014) 0.75

Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients? Genet Res Int (2017) 0.75

Incredibly late thromboses in first generation drug eluting stents: a case series. Cases J (2009) 0.75

The Resolute zotarolimus-eluting stent and diabetes mellitus. Indian Heart J (2012) 0.75

Short-term clinical outcomes after hybrid coronary revascularization versus off-pump coronary artery bypass for the treatment of multivessel or left main coronary artery disease: a meta-analysis. Coron Artery Dis (2015) 0.75

Intensity of antiplatelet therapy and percutaneous coronary intervention. F1000 Med Rep (2009) 0.75

Clinical roles of calcium channel blockers in ischemic heart diseases. Hypertens Res (2017) 0.75

Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial. Trials (2013) 0.75

Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study. Medicine (Baltimore) (2016) 0.75

Application of the Transtheoretical Model to Exercise Behavior and Physical Activity in Patients after Open Heart Surgery. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2015) 0.75

Clopidogrel Therapy Discontinuation Following Drug Eluting Stent Implantation in Real World Practice in Israel. Cardiol Res (2012) 0.75

Conservative pharmacotherapy vs. staged percutaneous coronary intervention for non-culprit vessels in patients with ST-segment elevation myocardial infarction. Exp Ther Med (2016) 0.75

Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION). Maedica (Buchar) (2013) 0.75

The current state of endovascular therapy in the evaluation and management of renovascular disease. Semin Intervent Radiol (2009) 0.75

Temporal trends and in-hospital outcomes of primary percutaneous coronary intervention in nonagenarians with ST-segment elevation myocardial infarction. Korean J Intern Med (2015) 0.75

Safety and efficacy of overlapping homogenous drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction Registry. J Korean Med Sci (2012) 0.75

Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. BMJ Open (2016) 0.75

Clopidogrel-Induced Recurrent Polyarthritis. J Investig Med High Impact Case Rep (2013) 0.75

[Coronary stent thrombosis: what's new in 2011?]. Herz (2011) 0.75

Articles by these authors

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation (2009) 35.24

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation (2003) 23.97

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07

Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation (2002) 21.38

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 20.67

Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation (2010) 19.30

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 18.90

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 16.52

Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25

A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22

Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05

Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA (2009) 13.69

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29

Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation (2006) 13.21

Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation (2004) 13.07

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA (2008) 12.36

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88

Universal definition of myocardial infarction. Circulation (2007) 11.69

Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med (2009) 11.51

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke (2010) 10.66

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol (2007) 10.19

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96

ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation (2006) 9.83

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation (2009) 9.26

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation (2010) 9.07

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation (2002) 9.04

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation (2008) 8.94